Differential expression of menin in sporadic pituitary adenomas

• Published in: Endocrine-related cancer Vol. 11; no. 2; pp. 333 - 344
• Main Authors: Theodoropoulou, M, Cavallari, I, Barzon, L, D'Agostino, D M, Ferro, T, Arzberger, T, Gr√ºbler, Y, Schaaf, L, Losa, M, Fallo, F, Ciminale, V, Stalla, G K, Pagotto, U
• Format: Journal Article
• Language: English
• Published: England BioScientifica 01.06.2004
• Subjects: Adenoma - metabolism; Adenoma - pathology; Adolescent; Adult; Aged; Aged, 80 and over; Comparative Study; Female; Genes, Tumor Suppressor; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness - pathology; Pituitary Gland - metabolism; Pituitary Gland - pathology; Pituitary Neoplasms - metabolism; Pituitary Neoplasms - pathology; Proto-Oncogene Proteins - metabolism; Support, Non-U.S. Gov't
• ISSN: 1351-0088; 1479-6821
• DOI: 10.1677/erc.0.0110333

Pituitary adenomas represent one of the key features of multiple endocrine neoplasia type 1. The gene involved in this syndrome (MEN1) is a putative tumor suppressor, that codes for a 610-amino acid nuclear protein termed 'menin'. Analyses of sporadic pituitary adenomas have so far failed to reveal MEN1 mutations or defects in MEN1 transcription in these tumors. In the present study we detected menin protein expression in a panel of normal and tumoral pituitary tissues, using a monoclonal antibody against the carboxy-terminus of menin. In the normal human pituitary gland, strong nuclear staining for menin was detectable in the majority of the endocrine cells of the anterior lobe, without a clear association with a particular hormone-producing type. In sporadic pituitary adenomas, menin expression was variable, with a high percentage of cases demonstrating a significant decrease in menin immunoreactivity when compared with the normal pituitary. Interestingly, metastatic tissues derived from one pituitary carcinoma had no detectable menin levels. Altogether, our data provide the first information regarding the status of menin expression in human normal and neoplastic pituitary as determined by immunohistochemistry (IHC).